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Abstract:  Abdominal  venous  thrombosis  may  present  as  splanchnic  venous  thrombosis  (SVT) 
(occlusion  of  portal,  splenic,  superior  or  inferior  mesenteric  veins)  or  Budd
(BCS) (thrombosis of inferior vena cava and/or hepatic veins). The aim of this review is to report 
the scanty data available for SVT in the South Mediterranean area. In one Egyptian study, the 
possible circumstantial risk factors for portal vein 
19% neonatal sepsis, 8.7% umbilical catheterization, 6% severe gastroenteritis and dehydration. 
Another Egyptian study concluded that hereditary thrombophilia was common in children with 
PVT (62.5%), the commonest being factor V Leiden mutation (FVL) (30%). Concurrence of more 
than one hereditary thrombophilia was not uncommon (12.5%). The first international publication 
on hepatic veno-occlusive disease (VOD) in Egypt was in 1965 in children who rapidly develop
abdominal  distention  with  ascites  and  hepatomegaly.  This  disease  was  more  frequent  in 
malnourished  children  coming  from  rural  areas;  infusions  given  at  home  may  contain  noxious 
substances that were hepatotoxic and infections might play a role. VOD of chil
nowadays.  Data  from  South  Mediterranean  area  are  deficient  and  this  may  be  attributable  to 
reporting in local medical journals that are difficult to access. Medical societies concerned with this 
topic could help distribute this informa
 
Introduction: In general practice, physicians pay extra 
attention  to  the  thrombosis  of  coronary,  pulmonary, 
mesenteric or cerebral circulation but not to abdomi
venous circulation. Thrombotic occlusion of all major 
vessels  of  abdominal  cavity  has  severe  clinical 
consequences and chronic complications.
1 
Thrombosis  in  the  major  vessels  of  the  abdomen 
causes  a  wide  spectrum  of  clinical  pictures  ranging 
from a totally asymptomatic patient to a patient with 
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Abdominal  venous  thrombosis  may  present  as  splanchnic  venous  thrombosis  (SVT) 
(occlusion  of  portal,  splenic,  superior  or  inferior  mesenteric  veins)  or  Budd- 
(BCS) (thrombosis of inferior vena cava and/or hepatic veins). The aim of this review is to report 
the scanty data available for SVT in the South Mediterranean area. In one Egyptian study, the 
possible circumstantial risk factors for portal vein thrombosis (PVT) were found in 30% of cases:  
19% neonatal sepsis, 8.7% umbilical catheterization, 6% severe gastroenteritis and dehydration. 
Another Egyptian study concluded that hereditary thrombophilia was common in children with 
est being factor V Leiden mutation (FVL) (30%). Concurrence of more 
than one hereditary thrombophilia was not uncommon (12.5%). The first international publication 
occlusive disease (VOD) in Egypt was in 1965 in children who rapidly develop
abdominal  distention  with  ascites  and  hepatomegaly.  This  disease  was  more  frequent  in 
malnourished  children  coming  from  rural  areas;  infusions  given  at  home  may  contain  noxious 
substances that were hepatotoxic and infections might play a role. VOD of childhood is rarely seen 
nowadays.  Data  from  South  Mediterranean  area  are  deficient  and  this  may  be  attributable  to 
reporting in local medical journals that are difficult to access. Medical societies concerned with this 
topic could help distribute this information.   
In general practice, physicians pay extra 
attention  to  the  thrombosis  of  coronary,  pulmonary, 
mesenteric or cerebral circulation but not to abdominal 
venous circulation. Thrombotic occlusion of all major 
vessels  of  abdominal  cavity  has  severe  clinical 
 
Thrombosis  in  the  major  vessels  of  the  abdomen 
causes  a  wide  spectrum  of  clinical  pictures  ranging 
from a totally asymptomatic patient to a patient with 
acute abdominal pain and even impending liver failure 
in  patients  with  underlying  chronic  liver  disease
Thrombosis involving the liver vasculature is rare but 
constitutes a potentially life-threatening situation.
Abdominal  venous  thrombosis  may  present  as 
Budd- Chiari Syndrome (BCS) (thrombosis of inferior 
vena cava and/or hepatic veins) or splanchnic
thrombosis  (SVT)  (occlusion  of  portal,  splenic, 
superior or inferior mesenteric veins). Hereditary and 
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Abdominal  venous  thrombosis  may  present  as  splanchnic  venous  thrombosis  (SVT) 
  Chiari  Syndrome 
(BCS) (thrombosis of inferior vena cava and/or hepatic veins). The aim of this review is to report 
the scanty data available for SVT in the South Mediterranean area. In one Egyptian study, the 
thrombosis (PVT) were found in 30% of cases:  
19% neonatal sepsis, 8.7% umbilical catheterization, 6% severe gastroenteritis and dehydration. 
Another Egyptian study concluded that hereditary thrombophilia was common in children with 
est being factor V Leiden mutation (FVL) (30%). Concurrence of more 
than one hereditary thrombophilia was not uncommon (12.5%). The first international publication 
occlusive disease (VOD) in Egypt was in 1965 in children who rapidly develop 
abdominal  distention  with  ascites  and  hepatomegaly.  This  disease  was  more  frequent  in 
malnourished  children  coming  from  rural  areas;  infusions  given  at  home  may  contain  noxious 
dhood is rarely seen 
nowadays.  Data  from  South  Mediterranean  area  are  deficient  and  this  may  be  attributable  to 
reporting in local medical journals that are difficult to access. Medical societies concerned with this 
acute abdominal pain and even impending liver failure 
in  patients  with  underlying  chronic  liver  disease.
1 
Thrombosis involving the liver vasculature is rare but 
threatening situation.
2 
Abdominal  venous  thrombosis  may  present  as 
Chiari Syndrome (BCS) (thrombosis of inferior 
vena cava and/or hepatic veins) or splanchnic venous 
thrombosis  (SVT)  (occlusion  of  portal,  splenic, 
superior or inferior mesenteric veins). Hereditary and Mediterr J Hematol Infect Dis 2011; 3: Open Journal System   
 
acquired  risk  factors  have  been  implicated  in  the 
etiopathogenesis of abdominal venous thrombosis.
3,4 
Normal  coagulation  hemostasis  involves  the 
interaction  of  an  initial  vascular  reaction 
(vasoconstriction), thrombocytic activation (white clot 
formation) and formation of thrombin via activation of 
coagulation  cascade.  The  balance  between  the  forces 
favoring formation of a clot and forces against it is the 
normal  state  which  is  controlled  with  very  delicate 
systems.
1 
Predisposition  to  venous  and  occasionally  arterial 
thromboembolism is termed thrombophilia.
5,6,7,8 
Thrombophilia is a term  which is proposed as an 
opposite term against hemophilia. Thrombophilia can 
be  defined  as  a  disturbed  state  of  the  coagulation-            
fibrinolysis balance in favor of thrombosis formation 
(congenital  or  acquired  in  adult  life)  in  which 
thrombosis (in arterial and/ or venous vasculature) is 
observed more frequently than normal population. For 
the  gastroenterologists  and  surgeons,  the  congenital 
and acquired causes of the thrombophilia are important 
not only due to their potential risks to patients’ lives 
but also their preventability with the advent of genetic 
tests  and  surveillance  and  their  treatability  with new 
invasive  techniques  and  new  anticoagulant  drugs. 
Thrombophilia  can  be  grouped  under  two  major 
headlines: inherited and acquired.
1 
Inherited  thrombophilias  include:  factor  V  Leiden 
mutation,  prothrombin  gene  mutation,  protein  C  and 
protein S deficiencies, antithrombin deficiency. While 
acquired  causes  of  thrombophilia  include:  oral 
contraceptive  use,  pregnancy,  puerperium,  surgery, 
immobilization  and  anti-phospholipid  syndrome.  Age 
is considered as an independent risk factor for venous 
thrombosis  mainly  due  to  inactivity,  co-morbid 
illnesses and degenerative changes. Malignant disease 
is  also  important;  with  thrombosis  related  deaths 
ranking in the second place among all causes of death 
in  this  patient  population.
9,10,11  Myeloproliferative 
neoplasms  (MPN)  form  a  group  of  special  blood 
disorders which may be termed as half-malignant due 
to  their  natural  course  and  these  patients  frequently 
suffer  from  venous  thrombosis.  Thrombocytosis  and 
the  increased  hematocrit,  which  are  natural 
characteristics  of  these  disorders,  also  cause 
thrombosis  in  the  venous  systems.
12  A  substantial 
number  of  patients  with  SVT,  especially  portal  vein 
thrombosis  (PVT)  were  found  to  be  carriers  of 
mutation in Janus kinase 2 (JAK2) in the absence of 
overt signs of chronic myeloproliferative disease.
13 
Both  abdominal  venous  thrombosis,  BCS 
(thrombosis of inferior vena cava and/or hepatic veins) 
and  SVT  (occlusion  of  portal,  splenic,  superior  or 
inferior  mesenteric  veins)  have  been  reported  in 
children. However, reports in children are scanty and 
few  studies  coming  from  the  South  Mediterranean 
region have comprehensively evaluated prothrombotic 
risk factors in BCS and PVT in children. The aim of 
this  review  is to  report  the  scanty data  available for 
SVT in the South Mediterranean area. 
 
Portal  Vein  Thrombosis  (PVT):  The  portal  vein  is 
considered the backbone of the portal venous system 
that allows for blood from the digestive organs to flow 
towards the liver. PVT refers to the total or near total 
obstruction  of  blood  flow  secondary  to  thrombus 
formation.  This  thrombus  may  extend  towards  liver 
involving  intrahepatic  portal  veins  or  may  extend 
distally to involve splenic veins or mesenteric  veins. 
On  some  occasions  extensive  involvement  of  all  of 
these  vessels  may  occur  with  an  increased  risk  of 
intestinal ischemia. Therefore, the involved segment of 
portal venous system and the degree of compensatory 
mechanisms determine the clinical presentation. PVT 
has  considerable  consequences  for  the  liver.  Upon 
cessation of blood flow liver loses about two thirds of 
its blood supply. Interestingly, while the acute arterial 
blockage  usually  results  in  severe  hepatic  failure  or 
death, PVT is tolerated well and the patients are almost 
asymptomatic due to compensatory mechanisms. First 
compensatory mechanism is the well known “arterial 
vasodilation” of the hepatic artery (which is a vascular 
reflex seen in every dual-vessel supplied organ) also 
observed during portal vein clamping in liver surgery.
14 
This “arterial rescue” stabilizes the liver functions at a 
normal  level  in  the  very  acute  stages  of  PVT.  The 
second  rescue  mechanism  is  the  “venous  rescue” 
involving  rapid  development  of  collateral  vessels  to 
bypass the obstructed segment. These vessels begin to 
form in a few days after the obstruction and organize 
into  a  cavernomatous  transformation  in  3-5  wk.
15,16 
Acute  PVT  can  rather  be  called  “acute  mesenteric 
thrombosis”  due  to  extensive  co-involvement  of  the 
superior mesenteric vein and branches. This condition 
has  very  acute  deleterious  effects  over  intestinal 
circulation  compromising  the  patient’s  life  before 
development  of  portal  hypertension  and  its 
consequences.
1  Besides  these  compensatory 
mechanisms, liver bears the burden of decreased blood 
to  some  extent.  The  decreased  portal  blood  flow 
stimulates apoptosis in hepatocytes of rats when portal 
vein is obliterated in a gradual fashion
17 and increases 
mitotic activity of hepatocytes in the unaffected lobe. 
The  latter  effect  is  well  known  from  selective  pre-
surgery  portal  vein  obliteration  performed  in  an 
intention to stimulate the hypertrophy of the opposite 
lobe of the liver used in cancer surgery. Gradual loss of 
hepatic mass may be responsible for the occurrence of 
mild  to  moderate  degree  of  hepatic  synthetic 
dysfunction observed in advanced stages. Mediterr J Hematol Infect Dis 2011; 3: Open Journal System   
 
The term PVT refers to thrombosis developing in 
the trunk of the portal vein from where it can extend 
toward  the  liver  affecting  the  right  and  the  left 
branches.  It  can  also  extend  to  the  splenic  and  the 
superior mesenteric veins.
18 Thrombosis of the portal 
venous system refers to thrombosis at any of the above 
sites.
19,20  Extrahepatic  portal  vein  obstruction 
(EHPVO)  with  cavernous  transformation  is  an 
important cause of portal hypertension in children. It is 
associated with gastrointestinal bleeding mainly from 
oesophageal and/or gastric varices.
21 In Asia, EHPVO 
is a common cause of portal hypertension, accounting 
for  30%  of  all  variceal  bleeding,  and  is  the  leading 
cause of variceal bleeding in children.
22 
 
Etiology: The precise etiology of the development of 
EHPVO in the majority of these children is unknown. 
The  predisposing  factors  are  believed  to  be  the 
following:  conditions  that  directly  injure  the  vessel, 
rare portal vein congenital anomalies, and a group of 
systemic  causes  such  as  neonatal  sepsis,  abdominal 
sepsis,  dehydration,  multiple  exchange  transfusions, 
and  hypercoagulable  states.  Prothrombotic  disorders 
include  deficiencies  in  the  naturally  occurring 
anticoagulants (protein C, protein S, and antithrombin) 
and factor V Leiden and prothrombin gene mutations 
(PT20210  G/A).  Acquired  prothrombotic  disorders 
include  the  antiphospholipid  syndrome,  paroxysmal 
nocturnal haemoglobinuria, and MPNs: polycythaemia 
vera  (PV),  essential  thrombocythaemia  (ET),  and 
idiopathic myelofibrosis.
23 Recent reports confirm that 
the JAK2 V617F mutation is strongly implicated in the 
pathogenesis  of  myeloproliferative  disorder  that  may 
be associated with increased rates of thrombosis.
24,25 
The possible circumstantial risk factors for EHPVO 
were  analyzed  in  69  children  presenting  to  our 
Pediatric Hepatology Unit at Cairo University, between 
1995 and 1997 and we found that 21 (30%) had past 
history relevant to the etiology of EHPVO: 19% had 
history  of  neonatal  sepsis,  6  (8.7%)  underwent 
umbilical  catheterization  for  exchange  transfusion,  4 
(6%) had at least one episode of severe gastroenteritis 
and dehydration. None had a history of any abdominal 
surgery or trauma.
26 
The risk of development of PVT was studied at the 
neonatal  intensive  care  (NICU)  in  our  hospital  in 
newborns that underwent umbilical vein catheterization 
for  exchange  transfusion.  The  study  included  128 
newborns  presenting  to  NICU,  from  January  1996-
December  1996,  with  severe  neonatal  indirect 
hyperbilirubinemia  with  or  without  septicemia.  Two 
out of 128 developed PVT as seen in the first Doppler 
study  during  their  stay  in  NICU.  Portal  vein 
cavernoma,  denoting  collaterals  around  the  occluded 
portal  vein,  was  seen  as  early  as  two  weeks  post-
exchange  transfusion.  The  whole  group  of  newborns 
was followed up, at 3-monthly intervals for 12 months, 
with abdominal ultrasound and Doppler study and none 
of the remaining 126 cases developed EHPVO beyond 
the  neonatal  period.    One  of  the  2  patients  who 
developed  PVT  was  diagnosed  as  Crigler-Najjar 
syndrome  type  1  and  underwent  3  exchange 
transfusions  before  starting  home  phototherapy.  The 
second  case  also  did  exchange  transfusion  thrice  for 
severe neonatal indirect hyperbilirubinemia and sepsis; 
her initial serum bilirubin on the second day of life was 
35 mg/dl.
26 
Some  hereditary  causes  for  thrombophilia  were 
studied  at  the  Pediatric  Hepatology  Unit  at  Cairo 
University,  Egypt,  in  a  group  of  40  children  with 
EHPVO  as  possible  risk  factor  for  development  of 
PVT (Table 1).
27 
 
Table 1: Characteristics of the 40 cases with EHPVO 
Age: mean (range)       9.4 (1–15 years) 
Sex: ratio (M/F)         2.1:1 (27/13) 
Main presenting symptoms 
Hematemesis (n/%)       7/17.5% 
Melena (n/%)         1/2.5% 
Hematemesis and melena (n/%)     15/37.5% 
Abdominal distention (n/%)     11/27.5% 
Abdominal pain (n/%)       3/7.5% 
Accidentally detected splenomegaly (n/%)   3/7.5% 
Circumstantial risk factors 
Neonatal sepsis       2/10% 
Umbilical sepsis       3/5% 
Umbilical catheterization     2/5% 
Severe gastroenteritis and dehydration   None 
Family history of thromboembolism  None 
Consanguinity of parents       13/32.5% 
Splenomegaly         35/87.5% 
Splenectomy         5/12.5% 
Ultrasound findings 
Portal vein obstruction       33/82.5% 
Portal vein cavernoma       7/17.5% 
Upper gastrointestinal endoscopy findings 
Esophageal varices       40/100% 
Eradicated varices by sclerotherapy   6/15% 
Gastric varices        10/25% 
Congestive gastropathy       3/7.5% 
 
They included factor V Leiden (FVL) mutation, Factor 
II (prothrombin G20210A) mutation, activated protein 
C resistance (APCR), assay of protein C, protein S and 
antithrombin  and  mutation  in  tetrahydrofolate 
reductase  (MTFHR)  gene  (Table  2)
27,28.  Among  the 
patients, 11 had protein C deficiency (27.5%), 1 was 
deficient in antithrombin (2.5%), none had protein S 
deficiency, APCR was detected in 12 cases (30%), the Mediterr J Hematol Infect Dis 2011; 3: Open Journal System   
 
same 12 cases were heterozygous for FVL mutation, 
and none was homozygous.  
 
Table  2:  Frequency  of  protein  C,  protein  S,  antithrombin 
deficiencies, APCR, and factor V and factor II mutations among the 
40 cases with EHPVO. 
Thrombophilia   n   % 
     
Single factor abnormality   20  50 
 
Protein C deficiency   8  20 
 
Protein S deficiency   0  0 
 
Antithrombin III deficiency   0  0 
 
Factor V mutation + APCR   9  22.5 
 
Factor II mutation   3  7.5 
 
MTFHR C667T mutation  2  5 
Combined factors abnormalities   5  12.5 
 
Protein C deficiency + antithrombin III 
deficiency   1  2.5 
 
Protein C deficiency + factor V mutation 
+ APCR   1  2.5 
 
Protein C deficiency + factor II mutation   1  2.5 
 
Factor V mutation + APCR + factor II 
mutation   2  5 
 
Factor V mutation + APCR + MTFHR 
C667T mutation  2  5 
Patients  with  no  detectable 
abnormalities  
15  37.5 
 
Factor II mutation was found in six cases (15%); all 
were  heterozygous.  MTFHR  C667T  mutation  was 
found in 4 cases (2 homozygous and 2 heterozygous). 
Only one  of  the  controls was heterozygous  for  FVL 
mutation  and  had  APCR,  4  were  heterozygous  for 
MTFHR C667T mutation and no other thrombophilia 
was detected in the control group. FVL mutation and 
APCR  were  significantly  more  prevalent  in  patients 
than controls (p=0.03), while no statistically significant 
difference  was  found  between  cases  and  controls  as 
regards  the  prevalence  of  factor  II  mutation.  The 
relative  risk  of  development  of  PVT  with  FVL 
mutation was calculated using the odds ratio and was 
found  to  be  6,  which  is  statistically  significant 
(p<0.05). We concluded that hereditary thrombophilia 
was  common  in  children  with  EHPVO  (62.5%),  the 
commonest being FVL mutation (30%). Concurrence 
of  more  than  one  hereditary  thrombophilia  is  not 
uncommon  (12.5%).  Circumstantial  risk factors  were 
not more significantly prevalent among patients with 
hereditary  thrombophilia  than  among  those  with  no 
detectable abnormalities in anticoagulation.  
 
Hepatic Venous Outflow Obstruction: Obstruction to 
the  hepatic  venous  outflow  includes  sinusoidal 
obstruction  syndrome  also  known  as  hepatic  veno-
occlusive disease (VOD) and venous obstruction from 
the level of the small hepatic veins to the junction of 
the inferior vena cava to the right atrium also known as 
Budd-Chiari syndrome (BCS). 
The  first  report  of  hepatic  VOD  was  in  children. 
Four local reports from Egypt referred to children who 
rapidly develop abdominal distention with ascites and 
hepatomegaly. Dilated veins soon become apparent in 
their  anterior  abdominal  walls,  the  spleen  does  not 
enlarge at the onset, and jaundice is either absent or 
slight.
29,30,31,32 
Professor  Mohammad  Safouh,  the  father  of 
Pediatric  Hepatology  in  Egypt,  published  his  first 
international  report  on  VOD  in  1965.
33  These  cases 
were frequently seen at that time. They reported on 59 
cases presenting to Cairo University Pediatric Hospital 
over 4 years. There ages ranged between 1-12 years, 
however,  47  patients  were  below  4  years; 
males/females were 36/23. All cases came from a poor 
social  class  and  the  majority  lived  in  rural  areas. 
Abdominal distention was the presenting feature. In 55 
it was rapid in onset. The liver was large and firm as a 
rule. Ascites was always present and dilated veins were 
seen on the abdominal wall in the epigastrium and over 
the lower sternal border. The spleen usually was not 
enlarged. The weight and height were below average. 
Jaundice was absent or just a tinge. Lower limb edema 
was present in a third of the cases. Four cases were 
above  6  years  of  age  and  had  a  chronic  form  with 
marked enlargement of the liver and spleen, with little 
or no ascites. A history of preceding fever was reported 
shortly before the onset in half of the cases. Diarrhea, 
in the form of dysentery was not uncommon before the 
onset.  Dietary  survey  done  for  17  cases  revealed 
reduced protein intake and excessive consumption of 
vegetables as well as plant seeds infusions. Changes in 
blood  counts,  erythrocyte  sedimentation  rate,  serum 
proteins and transaminases were unremarkable, but the 
ascetic fluid was rich in protein. Sixteen autopsies were 
performed  and  revealed  obliteration  of  the  main 
hepatic veins and their ostia in the inferior vena cava 
by organized thrombi. Extension of the obliteration in 
the hepatic veins was variable. Liver showed advanced 
nutmeg appearance in acute cases. In one patient with 
advanced  disease  the  liver  was  finely  nodular.  Liver 
histology  showed  centrilobular  necrosis  and  fatty 
changes  in  the  periphery  of  the  lobules.  Portal  tract 
thickening was rarely marked. Management was in the 
form  of  high  protein  diet,  tapping  of  ascites,  which 
rapidly  re-accumulated,  diuretics  and  sometimes 
plasma transfusions. Some operative procedures were 
tried  like  omentopexy,  hepatic  artery  ligation  and 
laparotomy  to  relieve  an  obstructed  hernia.  Three 
chronic  cases  had  a  stationary  course  with 
disappearance of ascites. Most acute cases died within Mediterr J Hematol Infect Dis 2011; 3: Open Journal System   
 
a few months. Hematemesis occurred in only one case. 
Jaundice rarely developed, and although jaundice often 
deepened  before  death,  some  patients  died  anicteric. 
This  report  concluded  that  this  disease  was  more 
frequent in malnourished children coming from rural 
areas.  Infusions  given  at  home  may  contain  noxious 
substances that were hepatotoxic. Infections might play 
a role. Senecio poisoning was reported with a picture 
of  Chiari  syndrome.
34  However,  the  vegetables  and 
drinks commonly ingested by Egyptian children were 
not of the Senecio class but might have contaminated 
them.  
Classic hepatic VOD has become extremely rare in 
children  since  the  80s,  when  VOD  became  more 
commonly seen in adults as a complication of stem cell 
or  bone  marrow  transplantation.
35,36  This  marked 
reduction in the incidence of the disease in Egyptian 
children  may  be  attributed  to  improved  sanitary  and 
hygienic conditions that predispose to the disease.  
 
Conclusion: In view of the deficient reporting on SVT 
from  South  Mediterranean  countries,  despite  its 
deleterious effect on child health, both hereditary and 
acquired factors for thrombophilia and substantial risk 
factors need to be studied more in this region in this 
age group. Deficient data might also be attributable to 
reporting in local medical journals which are difficult 
to search for and access. Pediatric medical societies in 
countries of the region have to play a role in collecting 
available data and distributing information in a trial to 
reach  a  consensus  in  diagnosis  and  management  of 
such rare but serious condition. 
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